Nektar Therapeutics Costs and Expenses
Nektar Therapeutics (NKTR) reported Costs and Expenses of $52.47 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:CostsAndExpenses · last filed 2026-08-14
- Nektar Therapeutics costs and expenses for the quarter ending 2026-06-30 was $52.47M, a 10.69% increase year-over-year.
- Nektar Therapeutics costs and expenses for the quarter ending 2026-03-31 was $49.91M, a 9.24% decline year-over-year.
- Nektar Therapeutics costs and expenses for the quarter ending 2025-12-31 was $49.47M, a 233.66% increase year-over-year.
- Nektar Therapeutics costs and expenses for the quarter ending 2025-09-30 was $43.46M, a 25.67% decline year-over-year.
- Nektar Therapeutics costs and expenses for fiscal 2025 was $195.33M, a 4.07% decline from fiscal 2024.
- Nektar Therapeutics costs and expenses for fiscal 2024 was $203.63M, a 42.45% decline from fiscal 2023.
- Nektar Therapeutics costs and expenses for fiscal 2023 was $353.81M, a 24.44% decline from fiscal 2022.
- Nektar Therapeutics costs and expenses for fiscal 2022 was $468.22M, a 14.56% decline from fiscal 2021.
| Period end | Costs and Expenses 3 month | Costs and Expenses 3 month as first filed | Costs and Expenses 6 month | Costs and Expenses 9 month | Costs and Expenses 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $52.47M 10-Q · filed 2026-08-14 | $102.39M 10-Q · filed 2026-08-14 | $151.86M derived: sum of 3 quarters · filed 2026-08-14 | $195.32M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2026-03-31 | $49.91M 10-Q · filed 2026-05-08 | $99.39M derived: sum of 2 quarters · filed 2026-05-08 | $142.85M derived: sum of 3 quarters · filed 2026-05-08 | $190.25M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-12-31 | $49.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $92.93M derived: sum of 2 quarters · filed 2026-03-13 | $140.34M derived: sum of 3 quarters · filed 2026-08-14 | $195.33M 10-K · filed 2026-03-13 | |
| 2025-09-30 | $43.46M 10-Q · filed 2025-11-07 | $90.87M derived: sum of 2 quarters · filed 2026-08-14 | $145.86M 10-Q · filed 2025-11-07 | $160.69M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-06-30 | $47.41M 10-Q · filed 2026-08-14 | $102.40M 10-Q · filed 2026-08-14 | $117.23M derived: sum of 3 quarters · filed 2026-08-14 | $175.70M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-03-31 | $54.99M 10-Q · filed 2026-05-08 | $69.82M derived: sum of 2 quarters · filed 2026-05-08 | $128.29M derived: sum of 3 quarters · filed 2026-05-08 | $201.55M derived: sum of 4 quarters · filed 2026-05-08 | |
| 2024-12-31 | $14.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $73.30M derived: sum of 2 quarters · filed 2026-03-13 | $146.56M derived: sum of 3 quarters · filed 2026-03-13 | $203.63M 10-K · filed 2026-03-13 | |
| 2024-09-30 | $58.47M 10-Q · filed 2025-11-07 | $131.73M derived: sum of 2 quarters · filed 2025-11-07 | $188.80M 10-Q · filed 2025-11-07 | $246.19M derived: sum of 4 quarters · filed 2025-11-07 | |
| 2024-06-30 | $73.26M 10-Q · filed 2025-08-08 | $130.33M 10-Q · filed 2025-08-08 | $187.72M derived: sum of 3 quarters · filed 2025-08-08 | $256.73M derived: sum of 4 quarters · filed 2025-08-08 | |
| 2024-03-31 | $57.07M 10-Q · filed 2025-05-09 | $114.46M derived: sum of 2 quarters · filed 2025-05-09 | $183.47M derived: sum of 3 quarters · filed 2025-05-09 | $254.57M derived: sum of 4 quarters · filed 2025-05-09 | |
| 2023-12-31 | $57.40M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-14 | $126.40M derived: sum of 2 quarters · filed 2025-03-14 | $197.50M derived: sum of 3 quarters · filed 2025-03-14 | $353.81M 10-K · filed 2025-03-14 | |
| 2023-09-30 | $69.01M 10-Q · filed 2024-11-08 | $140.11M derived: sum of 2 quarters · filed 2024-11-08 | $296.41M 10-Q · filed 2024-11-08 | $370.90M derived: sum of 4 quarters · filed 2024-11-08 | |
| 2023-06-30 | $71.10M 10-Q · filed 2024-08-09 | $227.40M 10-Q · filed 2024-08-09 | $301.89M derived: sum of 3 quarters · filed 2024-08-09 | $379.82M derived: sum of 4 quarters · filed 2024-08-09 | |
| 2023-03-31 | $156.30M 10-Q · filed 2024-05-10 | $230.80M derived: sum of 2 quarters · filed 2024-05-10 | $308.72M derived: sum of 3 quarters · filed 2024-05-10 | $483.14M derived: sum of 4 quarters · filed 2024-05-10 | |
| 2022-12-31 | $74.49M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $152.42M derived: sum of 2 quarters · filed 2024-03-05 | $326.84M derived: sum of 3 quarters · filed 2024-03-05 | $468.22M 10-K · filed 2024-03-05 | |
| 2022-09-30 | $77.93M 10-Q · filed 2023-11-08 | $252.35M derived: sum of 2 quarters · filed 2023-11-08 | $393.73M 10-Q · filed 2023-11-08 | $531.65M derived: sum of 4 quarters · filed 2024-03-05 | |
| 2022-06-30 | $174.42M 10-Q · filed 2023-08-09 | $315.80M 10-Q · filed 2023-08-09 | $453.72M derived: sum of 3 quarters · filed 2024-03-05 | $592.24M derived: sum of 4 quarters · filed 2024-03-05 | |
| 2022-03-31 | $141.38M 10-Q · filed 2023-05-10 | $279.30M derived: sum of 2 quarters · filed 2024-03-05 | $417.82M derived: sum of 3 quarters · filed 2024-03-05 | $556.35M derived: sum of 4 quarters · filed 2024-03-05 | |
| 2021-12-31 | $137.92M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $276.44M derived: sum of 2 quarters · filed 2024-03-05 | $414.97M derived: sum of 3 quarters · filed 2024-03-05 | $548.01M 10-K · filed 2024-03-05 | |
| 2021-09-30 | $138.52M 10-Q · filed 2022-11-04 | $277.05M derived: sum of 2 quarters · filed 2022-11-04 | $410.09M 10-Q · filed 2022-11-04 | $544.27M derived: sum of 4 quarters · filed 2023-02-28 | |
| 2021-06-30 | $138.53M 10-Q · filed 2022-08-05 | $271.57M 10-Q · filed 2022-08-05 | $405.76M derived: sum of 3 quarters · filed 2023-02-28 | $538.84M derived: sum of 4 quarters · filed 2023-02-28 | |
| 2021-03-31 | $133.04M 10-Q · filed 2022-05-06 | $267.22M derived: sum of 2 quarters · filed 2023-02-28 | $400.31M derived: sum of 3 quarters · filed 2023-02-28 | $526.86M derived: sum of 4 quarters · filed 2023-02-28 | |
| 2020-12-31 | $134.18M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $267.27M derived: sum of 2 quarters · filed 2023-02-28 | $393.82M derived: sum of 3 quarters · filed 2023-02-28 | $578.03M 10-K · filed 2023-02-28 | |
| 2020-09-30 | $133.08M 10-Q · filed 2021-11-05 | $259.64M derived: sum of 2 quarters · filed 2021-11-05 | $443.84M 10-Q · filed 2021-11-05 | $587.34M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2020-06-30 | $126.56M 10-Q · filed 2021-08-06 | $310.76M 10-Q · filed 2021-08-06 | $454.26M derived: sum of 3 quarters · filed 2022-03-01 | $582.22M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2020-03-31 | $184.20M 10-Q · filed 2021-05-07 | $327.70M derived: sum of 2 quarters · filed 2022-03-01 | $455.66M derived: sum of 3 quarters · filed 2022-03-01 | $589.95M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2019-12-31 | $143.50M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $271.46M derived: sum of 2 quarters · filed 2022-03-01 | $405.74M derived: sum of 3 quarters · filed 2022-03-01 | $554.65M 10-K · filed 2022-03-01 | |
| 2019-09-30 | $127.96M 10-Q · filed 2020-11-06 | $262.24M derived: sum of 2 quarters · filed 2020-11-06 | $411.15M 10-Q · filed 2020-11-06 | $551.27M derived: sum of 4 quarters · filed 2021-02-26 | |
| 2019-06-30 | $134.28M 10-Q · filed 2020-08-07 | $283.19M 10-Q · filed 2020-08-07 | $423.31M derived: sum of 3 quarters · filed 2021-02-26 | $549.71M derived: sum of 4 quarters · filed 2021-02-26 | |
| 2019-03-31 | $148.91M 10-Q · filed 2020-05-08 | $289.03M derived: sum of 2 quarters · filed 2021-02-26 | $415.43M derived: sum of 3 quarters · filed 2021-02-26 | $529.54M derived: sum of 4 quarters · filed 2021-02-26 | |
| 2018-12-31 | $140.12M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $266.52M derived: sum of 2 quarters · filed 2021-02-26 | $380.63M derived: sum of 3 quarters · filed 2021-02-26 | $505.39M 10-K · filed 2021-02-26 | |
| 2018-09-30 | $126.40M 10-Q · filed 2019-11-07 | $240.51M derived: sum of 2 quarters · filed 2019-11-07 | $365.27M 10-Q · filed 2019-11-07 | $484.77M derived: sum of 4 quarters · filed 2020-02-28 | |
| 2018-06-30 | $114.12M 10-Q · filed 2019-08-09 | $238.87M 10-Q · filed 2019-08-09 | $358.37M derived: sum of 3 quarters · filed 2020-02-28 | $441.82M derived: sum of 4 quarters · filed 2020-02-28 | |
| 2018-03-31 | $124.76M 10-Q · filed 2019-05-09 | $244.26M derived: sum of 2 quarters · filed 2020-02-28 | $327.70M derived: sum of 3 quarters · filed 2020-02-28 | $412.94M derived: sum of 4 quarters · filed 2020-02-28 | |
| 2017-12-31 | $119.50M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | $202.94M derived: sum of 2 quarters · filed 2020-02-28 | $288.19M derived: sum of 3 quarters · filed 2020-02-28 | $367.35M 10-K · filed 2020-02-28 | |
| 2017-09-30 | $83.44M 10-Q · filed 2018-11-08 | $168.69M derived: sum of 2 quarters · filed 2018-11-08 | $247.85M 10-Q · filed 2018-11-08 | $317.45M derived: sum of 4 quarters · filed 2019-03-01 | |
| 2017-06-30 | $85.25M 10-Q · filed 2018-08-09 | $164.41M 10-Q · filed 2018-08-09 | $234.01M derived: sum of 3 quarters · filed 2019-03-01 | $303.24M derived: sum of 4 quarters · filed 2019-03-01 | |
| 2017-03-31 | $79.17M 10-Q · filed 2018-05-10 | $148.76M derived: sum of 2 quarters · filed 2019-03-01 | $218.00M derived: sum of 3 quarters · filed 2019-03-01 | $289.09M derived: sum of 4 quarters · filed 2019-03-01 | |
| 2016-12-31 | $69.60M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $138.83M derived: sum of 2 quarters · filed 2019-03-01 | $209.93M derived: sum of 3 quarters · filed 2019-03-01 | $278.29M 10-K · filed 2019-03-01 | |
| 2016-09-30 | $69.24M 10-Q · filed 2017-11-08 | $140.33M derived: sum of 2 quarters · filed 2017-11-08 | $208.69M 10-Q · filed 2017-11-08 | $277.43M derived: sum of 4 quarters · filed 2018-03-01 | |
| 2016-06-30 | $71.09M 10-Q · filed 2017-08-09 | $139.46M 10-Q · filed 2017-08-09 | $208.19M derived: sum of 3 quarters · filed 2018-03-01 | $267.73M derived: sum of 4 quarters · filed 2018-03-01 | |
| 2016-03-31 | $68.37M 10-Q · filed 2017-05-10 | $137.10M derived: sum of 2 quarters · filed 2018-03-01 | $196.63M derived: sum of 3 quarters · filed 2018-03-01 | $262.76M derived: sum of 4 quarters · filed 2018-03-01 | |
| 2015-12-31 | $68.73M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $128.27M derived: sum of 2 quarters · filed 2018-03-01 | $194.40M derived: sum of 3 quarters · filed 2018-03-01 | $260.15M 10-K · filed 2018-03-01 | |
| 2015-09-30 | $59.53M 10-Q · filed 2016-11-04 | $125.66M derived: sum of 2 quarters · filed 2016-11-04 | $191.42M 10-Q · filed 2016-11-04 | $248.46M derived: sum of 4 quarters · filed 2017-03-01 | |
| 2015-06-30 | $66.13M 10-Q · filed 2016-08-04 | $131.89M 10-Q · filed 2016-08-04 | $188.93M derived: sum of 3 quarters · filed 2017-03-01 | $241.48M derived: sum of 4 quarters · filed 2017-03-01 | |
| 2015-03-31 | $65.76M 10-Q · filed 2016-05-04 | $122.80M derived: sum of 2 quarters · filed 2017-03-01 | $175.35M derived: sum of 3 quarters · filed 2017-03-01 | $226.78M derived: sum of 4 quarters · filed 2017-03-01 | |
| 2014-12-31 | $57.04M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $109.59M derived: sum of 2 quarters · filed 2017-03-01 | $161.02M derived: sum of 3 quarters · filed 2017-03-01 | $217.19M 10-K · filed 2017-03-01 | |
| 2014-09-30 | $52.55M 10-Q · filed 2015-11-06 | $103.98M derived: sum of 2 quarters · filed 2015-11-06 | $160.15M 10-Q · filed 2015-11-06 | $227.19M derived: sum of 4 quarters · filed 2016-02-29 | |
| 2014-06-30 | $51.43M 10-Q · filed 2015-08-06 | $107.60M 10-Q · filed 2015-08-06 | $174.64M derived: sum of 3 quarters · filed 2016-02-29 | $242.08M derived: sum of 4 quarters · filed 2016-02-29 | |
| 2014-03-31 | $56.17M 10-Q · filed 2015-05-01 | $123.21M derived: sum of 2 quarters · filed 2016-02-29 | $190.65M derived: sum of 3 quarters · filed 2016-02-29 | $257.11M derived: sum of 4 quarters · filed 2016-02-29 | |
| 2013-12-31 | $67.04M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $134.47M derived: sum of 2 quarters · filed 2016-02-29 | $200.94M derived: sum of 3 quarters · filed 2016-02-29 | $269.05M 10-K · filed 2016-02-29 | |
| 2013-09-30 | $67.43M 10-Q · filed 2014-11-07 | $133.90M derived: sum of 2 quarters · filed 2014-11-07 | $202.01M 10-Q · filed 2014-11-07 | $266.54M derived: sum of 4 quarters · filed 2015-02-26 | |
| 2013-06-30 | $66.47M 10-Q · filed 2014-08-01 | $134.58M 10-Q · filed 2014-08-01 | $199.10M derived: sum of 3 quarters · filed 2015-02-26 | $250.41M derived: sum of 4 quarters · filed 2015-02-26 | |
| 2013-03-31 | $68.11M 10-Q · filed 2014-05-08 | $68.41M 10-Q · filed 2013-05-09 | $132.63M derived: sum of 2 quarters · filed 2015-02-26 | $183.95M derived: sum of 3 quarters · filed 2015-02-26 | $234.62M derived: sum of 4 quarters · filed 2015-02-26 |
| 2012-12-31 | $64.53M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-26 | $115.84M derived: sum of 2 quarters · filed 2015-02-26 | $166.51M derived: sum of 3 quarters · filed 2015-02-26 | $222.39M 10-K · filed 2015-02-26 | |
| 2012-09-30 | $51.31M 10-Q · filed 2013-11-07 | $101.98M derived: sum of 2 quarters · filed 2013-11-07 | $157.87M 10-Q · filed 2013-11-07 | $208.12M derived: sum of 4 quarters · filed 2013-11-07 | |
| 2012-06-30 | $50.67M 10-Q · filed 2013-08-09 | $106.55M 10-Q · filed 2013-08-09 | $156.80M derived: sum of 3 quarters · filed 2013-08-09 | $205.21M derived: sum of 4 quarters · filed 2013-08-09 | |
| 2012-03-31 | $55.88M 10-Q · filed 2013-05-09 | $106.13M derived: sum of 2 quarters · filed 2013-05-09 | $154.54M derived: sum of 3 quarters · filed 2013-05-09 | $206.13M derived: sum of 4 quarters · filed 2013-05-09 | |
| 2011-12-31 | $50.25M 10-K · filed 2012-02-29 | $98.66M derived: sum of 2 quarters · filed 2012-11-09 | $150.25M derived: sum of 3 quarters · filed 2012-11-09 | $195.42M 10-K · filed 2014-02-27 | |
| 2011-09-30 | $48.41M 10-Q · filed 2012-11-09 | $100.00M derived: sum of 2 quarters · filed 2012-11-09 | $145.17M 10-Q · filed 2012-11-09 | $211.02M derived: sum of 4 quarters · filed 2012-11-09 | |
| 2011-06-30 | $51.59M 10-Q · filed 2012-08-09 | $96.76M 10-Q · filed 2012-08-09 | $162.61M derived: sum of 3 quarters · filed 2012-08-09 | $206.76M derived: sum of 4 quarters · filed 2012-08-09 | |
| 2011-03-31 | $45.17M 10-Q · filed 2012-05-04 | $111.02M derived: sum of 2 quarters · filed 2012-05-04 | $155.17M derived: sum of 3 quarters · filed 2012-05-04 | $195.87M derived: sum of 4 quarters · filed 2012-05-04 | |
| 2010-12-31 | $65.85M 10-K · filed 2012-02-29 | $110.00M derived: sum of 2 quarters · filed 2012-02-29 | $150.70M derived: sum of 3 quarters · filed 2012-02-29 | $187.29M 10-K · filed 2013-03-01 | |
| 2010-09-30 | $44.15M 10-K · filed 2012-02-29 | $84.85M derived: sum of 2 quarters · filed 2012-02-29 | $121.44M 10-Q · filed 2011-11-04 | ||
| 2010-06-30 | $40.70M 10-K · filed 2012-02-29 | $77.29M 10-Q · filed 2011-08-05 | |||
| 2010-03-31 | $36.59M 10-K · filed 2012-02-29 | ||||
| 2009-12-31 | $167.06M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |